CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Millennium: The Takeda Oncology Company today announced its sales force ranked first in an independent assessment of hematology/oncology sales teams in the pharmaceutical industry. The survey was conducted by Health Strategies Group, an independent consultant and market research company, and ranked the sales teams of leading hematology/oncology companies based on their ability to build valuable relationships with oncologists.
The report, titled Hematologic Cancer Sales Opportunity Assessment, asked oncologists who treat hematologic cancers to rank their sales representatives based on the behaviors, knowledge and resources used to improve overall performance. According to those oncologists responding to the survey, relationship value occurs when:
The Millennium sales team outranked all other U.S. cancer companies. According to the survey, the relationship value average across companies was 26 percent (range 9 percent-46 percent). Millennium secured an average of 46 percent, leading the industry in relationship value.
“We are extremely impressed with the knowledge and professionalism of our field team, and this top ranking by an independent assessment confirms what we’ve known all along,” said Joseph Regan, Vice President, US Sales, Millennium. “Perhaps most impressive is Millennium’s ability to secure these high-quality relationships while marketing only one product, VELCADE®, for the treatment of multiple myeloma and mantle cell lymphoma. Our product benefits greatly from having an experienced and diligent sales team handling promotion, and in turn, our field is privileged to sell a product that is such an important treatment option for patients.”
The field team at Millennium consists of sales and medical professionals dedicated to promoting the Company’s market-leading drug VELCADE® (bortezomib), a treatment for patients with multiple myeloma. This team was expanded significantly in 2008 when Millennium was acquired by Takeda Pharmaceutical Company Limited (TSE:4502), Japan’s largest pharmaceutical company. Today, Millennium is Takeda’s center of excellence in oncology and is responsible for global strategies regarding discovery, development and commercialization.
For more information on the survey by Health Strategies Group, please visit www.healthstrategiesgroup.com.
VELCADE is co-developed by Millennium and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S., Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. VELCADE is approved in 92 countries and has treated more than 160,000 patients worldwide.
What is VELCADE® Used For?
VELCADE (bortezomib) is approved for the treatment of patients with multiple myeloma (a cancer of the plasma cells). VELCADE is also approved for the treatment of patients with mantle cell lymphoma (a cancer of lymph nodes) who have already received other treatments.
How is VELCADE administered?
VELCADE is prescribed by a physician experienced in the use of medications to treat cancer. It is administered as an injection into your vein (IV) by a health care professional.
Who Should Not Receive VELCADE?
Before you receive treatment with VELCADE, tell your doctor about all of your medical conditions. You should not receive VELCADE if you are:
The effects of VELCADE in children have not been evaluated.
What are the Possible Side Effects of VELCADE?
VELCADE can cause serious side effects including:
The most common side effects seen in patients receiving VELCADE include: thrombocytopenia, neutropenia, nausea, peripheral neuropathy, neuralgia (nerve pain), pyrexia (high temperature), diarrhea, anemia, leukopenia (low levels of white blood cells), decreased appetite, fatigue, constipation, vomiting, dehydration, dyspnea (difficulty breathing), cough, asthenia (low energy), insomnia (trouble sleeping), peripheral edema (swelling of the limbs), and headache.
What other information should you discuss with your doctor?
You should also tell your doctor if you:
The side effects of VELCADE may impair your ability to drive or operate machinery.
These are not all of the possible side effects with VELCADE. It is important to always contact your doctor if you experience any side effects while on VELCADE. If you have any questions about VELCADE, contact your doctor. Additional information is available on the VELCADE website at www.VELCADE.com.
Please see the full prescribing information for VELCADE including warnings and precautions.
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) in May, 2008. The Company's research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/media.
KEYWORDS: United States North America Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical Other Health Research Science